Background In this study, we aimed to compare the effectiveness and adverse reactions of
nirmatrelvir/ritonavir and molnupiravir in high-risk outpatients with coronavirus disease 2019 …

Background Current guidelines recommend using nirmatrelvir-ritonavir for coronavirus
disease 2019 (COVID-19) treatment, but its potential drug interactions and contraindications …

Objectives To assess and compare subsequent hospital admissions within 30 days for
patients after receiving a prescription for either oral nirmatrelvir/ritonavir or oral molnupiravir …

Background Nirmatrelvir/ritonavir was Korea's first oral antiviral agent to treat coronavirus
disease 2019 (COVID-19). We analyzed the nirmatrelvir/ritonavir prescription rate and …

At present, there are some differences in the research results of nirmatrelvir–ritonavir
compared with other antiviral drugs for the treatment of COVID‐19 patients. We aimed to …

Background Nirmatrelvir-ritonavir is highly effective in preventing severe coronavirus
disease 2019 (COVID-19) in high-risk patients with mild-to-moderate severity. However, real …

Background Molnupiravir and nirmatrelvir-ritonavir have emerged as promising options for
COVID-19 treatment, but direct comparisons of their effectiveness have been limited. This …

Background: Whether hospitalized patients benefit from COVID-19 oral antivirals is
uncertain. Objective: To examine the real-world effectiveness of molnupiravir and …

This study aimed to compare the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) with
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …

Abstract Background Coronavirus disease 2019 (COVID‐19) is a highly contagious,
airborne viral infection that can infect anyone. Those with certain underlying conditions may …